Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
Sponsor: Xencor, Inc.
Summary
The purpose of this study is to determine the safety and tolerability of XmAb657 in healthy participants and participants with autoimmune diseases. Participants will be given XmAb657 subcutaneously (SC) by injection under the skin.
Official title: A Phase 1, First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of XmAb657 in Healthy Participants and in Participants With Autoimmune Diseases
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-02-24
Completion Date
2028-10
Last Updated
2026-05-22
Healthy Volunteers
Yes
Interventions
XmAb657
Biological
Locations (1)
Xencor Investigative Site
Melbourne, Australia